These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33416954)

  • 1. Assessment of test-retest reproducibility of [
    Li S; Naganawa M; Pracitto R; Najafzadeh S; Holden D; Henry S; Matuskey D; Emery PR; Cai Z; Ropchan J; Nabulsi N; Carson RE; Huang Y
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1327-1338. PubMed ID: 33416954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Study of
    Drake LR; Wu Y; Naganawa M; Asch R; Zheng C; Najafzadeh S; Pracitto R; Lindemann M; Li S; Ropchan J; Labaree D; Emery PR; Dias M; Henry S; Nabulsi N; Matuskey D; Hillmer AT; Gallezot JD; Carson RE; Cai Z; Huang Y
    J Nucl Med; 2024 Feb; 65(3):462-9. PubMed ID: 38360052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive quantification of [
    Naganawa M; Gallezot JD; Li S; Nabulsi NB; Henry S; Cai Z; Matuskey D; Huang Y; Carson RE
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):113-121. PubMed ID: 39155309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vivo evaluation of [
    Li S; Cai Z; Zhang W; Holden D; Lin SF; Finnema SJ; Shirali A; Ropchan J; Carre S; Mercier J; Carson RE; Nabulsi N; Huang Y
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1952-1965. PubMed ID: 31175396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic evaluation and test-retest reproducibility of [
    Finnema SJ; Nabulsi NB; Mercier J; Lin SF; Chen MK; Matuskey D; Gallezot JD; Henry S; Hannestad J; Huang Y; Carson RE
    J Cereb Blood Flow Metab; 2018 Nov; 38(11):2041-2052. PubMed ID: 28792356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating infusion methods and simplified quantification of synaptic density
    Asch RH; Naganawa M; Nabulsi N; Huan Y; Esterlis I; Carson RE
    J Cereb Blood Flow Metab; 2023 Dec; 43(12):2120-2129. PubMed ID: 37669455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation, kinetic modeling, and test-retest reproducibility of [
    Bertoglio D; Zajicek F; Lombaerde S; Miranda A; Stroobants S; Wang Y; Dominguez C; Munoz-Sanjuan I; Bard J; Liu L; Verhaeghe J; Staelens S
    J Cereb Blood Flow Metab; 2022 Oct; 42(10):1867-1878. PubMed ID: 35570828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and 28-day test-retest repeatability and reproducibility of [
    Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cortical abnormalities of synaptic vesicle protein 2A in focal cortical dysplasia type II identified in vivo with
    Tang Y; Yu J; Zhou M; Li J; Long T; Li Y; Feng L; Chen D; Yang Z; Huang Y; Hu S
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3482-3491. PubMed ID: 34978594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.
    Bretin F; Bahri MA; Bernard C; Warnock G; Aerts J; Mestdagh N; Buchanan T; Otoul C; Koestler F; Mievis F; Giacomelli F; Degueldre C; Hustinx R; Luxen A; Seret A; Plenevaux A; Salmon E
    Mol Imaging Biol; 2015 Aug; 17(4):557-64. PubMed ID: 25595813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
    Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of SV2A Binding in Rodent Brain Using [
    Sadasivam P; Fang XT; Toyonaga T; Lee S; Xu Y; Zheng MQ; Spurrier J; Huang Y; Strittmatter SM; Carson RE; Cai Z
    Mol Imaging Biol; 2021 Jun; 23(3):372-381. PubMed ID: 33258040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme.
    Chen L; Nabulsi N; Naganawa M; Zasadny K; Skaddan MB; Zhang L; Najafzadeh S; Lin SF; Helal CJ; Boyden TL; Chang C; Ropchan J; Carson RE; Villalobos A; Huang Y
    J Nucl Med; 2016 Sep; 57(9):1448-53. PubMed ID: 27199356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.